当前位置:

DC-CIK细胞技术平台
2017-05-25
DC-CIK.png


DC-CIK治疗技术是通过采集外周全血,利用现代细胞生物技术,经分离、再分别诱导、激活、扩增DC和CIK细胞,然后将DC细胞与CIK细胞按一定比例混合共培养,制备出一种具有抗肿瘤活性的免疫细胞群,用于癌症防治和改善机体免疫功能。


功能

Ø  广谱性杀伤肿瘤细胞,尤其是清除血液中的循环肿瘤细胞

Ø  通过分泌多种细胞因子激活和提高自身免疫系统的能力;

Ø  抑制肿瘤微转移、复发,阻抑肿瘤的发展;

Ø  明显提高患者生活质量,延长患者的生存期。


产品/技术优点

l  细胞制品于2005年获得中国国内**的国家食品药品监督管理局临床批文;

l  细胞制品CD3+/CD56+双阳率高,对癌细胞杀伤力强。


DC-CIK technology platform

DC-CIK, as clued by the name, is a mixture of immune effecter cells induced by cytokines and dendritic cells. The protocol includes, in the order, collection of blood from a donor, isolation of PBMC, separated induction and activation of DC and CIK from PBMC for a certain period of time, and then co-culturing of DC and CIK for another period of time until DC-CIK cell maturation for harvest. Our technology is highlighted by co-culture of dendritic cells and CIK cells, and such prepared DC-CIK cells have demonstrated to be powerful in tumor cell killing in vitro, and is expected to improve immune function and cancer prevention in vivo.

Features and Function

1.    Nonspecific, therefore, broad-spectrum of tumor cell killing activity, clean CTCs in blood;

2.    Secrete a variety of cytokines upon activation; therefore, may function in immune-system

       regulation in vivo;

3.    May inhibit, in vivo, tumor cell minor metastasis, reduce recurrence, and development;

4.    Improve cancer patients’ living quality, elongate patients’ survival term.

Highlights in our technology/products

1.    Co-culturing DC and CIK cells to render DC-CIK with high CD3 / CD56 double-positive ratio

       in cell prepration, thus possessing powerful killing to cancer cells

2.    The only cell products in China approved for clinical trial by State Food and Drug

       Administration


  • QQ咨询
  • 电话咨询
您是第 71514 位访客!